Last kr119.10 DKK
Change Today +1.30 / 1.10%
Volume 166.6K
LUN On Other Exchanges
As of 11:03 AM 10/22/14 All times are local (Market data is delayed by at least 15 minutes).

h lundbeck a/s (LUN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/24/14 - kr173.60
52 Week Low
10/14/14 - kr111.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for H LUNDBECK A/S (LUN)

Related News

No related news articles were found.

h lundbeck a/s (LUN) Details

H. Lundbeck A/S, a specialty pharmaceutical company, engages in the research, development, production, marketing, and sale of pharmaceuticals for the treatment of brain disorders in Europe, the United States, and internationally. The company’s principal products include Cipralex and Lexapro to treat depression, Ebixa for Alzheimer’s disease, Azilect to treat Parkinson’s disease, Xenazine for chorea associated with Huntington's disease, Sabril to treat epilepsy, Sycrest for bipolar disorder, and Onfi to treat Lennox-Gastaut syndrome. Its compounds in registration application include aripiprazole IM depot for the treatment of schizophrenia; Selincro for alcohol dependence; and Brintellix for the treatment of depression and anxiety. The company’s products in Phase III trials comprise IV carbamazepine for epilepsy; Brexpiprazole for psychiatric disorders; Desmoteplase for stroke; and Zicronapine for psychosis. Its products in Phase II trials include Tedatioxetine for depression and Lu AE58054 for Alzheimer's disease. H. Lundbeck A/S has strategic research collaboration with Ossianix, Inc. The company was founded in 1915 and is based in Valby, Denmark.

5,703 Employees
Last Reported Date: 08/7/14
Founded in 1915

h lundbeck a/s (LUN) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

h lundbeck a/s (LUN) Key Developments

GlaxoSmithKline Seeking Bids By Next Month For Older Drugs

GlaxoSmithKline plc (LSE:GSK) is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Potential bidders include Kohlberg Kravis Roberts & Co. L.P. (NYSE:KKR), Lupin Limited (BSE:500257) and H. Lundbeck A/S (CPSE:LUN) all of which are interested in acquiring rights to products in certain regions. Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two of the sources said. KKR has teamed up with Norgine B.V. in a bid to acquire some of GSK's drugs sold in Europe, said the same people. Lupin is also expected to participate in the second round of the auction and would be interested in products in the United States, said the sources. Other private equity funds with an interest in healthcare are also looking at some specific products. Some bidders might still emerge with an interest in the entire portfolio, although this scenario is seen as less likely. The sources said GSK was looking for a multiple of more than two times sales, suggesting a price of at least $3.2 billion. GSK, which is being advised by Lazard, aims to find buyers by the end of 2014. GSK, Lundbeck, KKR and Norgine all declined to comment.

U.S. FDA Accepts Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S's Filing for Review of Brexpiprazole

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced that the U.S. Food and Drug Administration has determined that the New Drug Application (NDA) for brexpiprazole for monotherapy in adult patients with schizophrenia and for adjunctive treatment of major depressive disorder (MDD) in adult patients is sufficiently complete to allow for a substantive review, and the NDA is considered filed as of September 9, 2014 (60 days after submission). The PDUFA date is July 11, 2015.

H. Lundbeck A/S Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 08:20 AM

H. Lundbeck A/S Presents at Öresund Investment Day- Life Science/Food, Sep-22-2014 08:20 AM. Venue: Medicon Village, Hörsalen, Scheelevägen 2, 223 63 Lund, Sweden. Speakers: Ulf Arne Wiinberg, Chief Executive Officer, President and Member of Executive Management.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LUN:DC kr119.10 DKK +1.30

LUN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $44.66 USD +0.86
Emergent Biosolutions Inc $21.31 USD +0.10
Impax Laboratories Inc $27.09 USD +0.08
Lupin Ltd 1,389 INR +21.15
Salix Pharmaceuticals Ltd $137.61 USD -2.94
View Industry Companies

Industry Analysis


Industry Average

Valuation LUN Industry Range
Price/Earnings 28.1x
Price/Sales 1.5x
Price/Book 1.6x
Price/Cash Flow 28.1x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact H LUNDBECK A/S, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at